Next Article in Journal
Features in the Lipid Status of Two Generations of Fingerlings (0+) of Atlantic Salmon (Salmo salar L.) Inhabiting the Arenga River (Kola Peninsula)
Next Article in Special Issue
Role of Pharmacogenetics in Hematopoietic Stem Cell Transplantation Outcome in Children
Previous Article in Journal
Molecular Mechanisms to Control Post-Transplantation Hepatitis B Recurrence
Previous Article in Special Issue
MicroRNA Profiling of B Cell Subsets from Systemic Lupus Erythematosus Patients Reveals Promising Novel Biomarkers
Article Menu
Issue 8 (August) cover image

Export Article

Open AccessReview
Int. J. Mol. Sci. 2015, 16(8), 17514-17534; doi:10.3390/ijms160817514

Molecular Classification and Pharmacogenetics of Primary Plasma Cell Leukemia: An Initial Approach toward Precision Medicine

1
Laboratory of Pre-Clinical and Translational Research, Reference Cancer Center of Basilicata, Scientific Institute of Hospitalization and Treatment, Rionero in Vulture 85028, Italy
2
Department of Clinical Sciences and Community Health, University of Milan and Hematology, Fondazione Cà Granda, Ospedale Maggiore Policlinico, Milan 20122, Italy
3
Scientific Direction, IRCCS-CROB, Referral Cancer Center of Basilicata, Rionero in Vulture 85028, Italy
These authors contributed equally to this work.
*
Author to whom correspondence should be addressed.
Academic Editor: Sabrina Angelini
Received: 13 June 2015 / Revised: 21 July 2015 / Accepted: 22 July 2015 / Published: 30 July 2015
(This article belongs to the Special Issue Pharmacogenetics and Personalized Medicine)
View Full-Text   |   Download PDF [1355 KB, uploaded 30 July 2015]   |  

Abstract

Primary plasma cell leukemia (pPCL) is a rare and aggressive variant of multiple myeloma (MM) which may represent a valid model for high-risk MM. This disease is associated with a very poor prognosis, and unfortunately, it has not significantly improved during the last three decades. New high-throughput technologies have allowed a better understanding of the molecular basis of this disease and moved toward risk stratification, providing insights for targeted therapy studies. This knowledge, added to the pharmacogenetic profile of new and old agents in the analysis of efficacy and safety, could contribute to help clinical decisions move toward a precision medicine and a better clinical outcome for these patients. In this review, we describe the available literature concerning the genomic characterization and pharmacogenetics of plasma cell leukemia (PCL). View Full-Text
Keywords: plasma cell leukemia; molecular profiling; risk stratification; pharmacogenetics; precision medicine plasma cell leukemia; molecular profiling; risk stratification; pharmacogenetics; precision medicine
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Supplementary material

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Simeon, V.; Todoerti, K.; La Rocca, F.; Caivano, A.; Trino, S.; Lionetti, M.; Agnelli, L.; De Luca, L.; Laurenzana, I.; Neri, A.; Musto, P. Molecular Classification and Pharmacogenetics of Primary Plasma Cell Leukemia: An Initial Approach toward Precision Medicine. Int. J. Mol. Sci. 2015, 16, 17514-17534.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top